CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is actually  a   biotech that has been effective conscientiously but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix. In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of prospective […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective conscientiously but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn's inventories of leronlimab are actually building up, whether they will ever be being used is actually an open question.


While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV have been closing.

I'm composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. My first CytoDyn post, "CytoDyn: What to be able to Do When It's Too Good to be able to Be True?", set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire job interview that I came away with an inadequate viewpoint of the company.

Irony of irony, my bad opinion of the business enterprise has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc.... has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today's payment of $3.5 zillion transfers ownership of this expertise and also connected intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance.... milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) plus the very first new drug application endorsement ($five million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn's leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and numerous indications, it has this single remedy in addition to a "broad pipeline of indications" because it puts it. I call such pipelines, "pipedots." In CytoDyn's situation it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its website (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease types, multiple delivering presentations and multiple publications.

Can all this be smoke and mirrors? That is a question I have been asking myself with the really beginning of the interest of mine in this business. Judging by the multiples of thousands of several commentary on listings accessible via Seeking Alpha's CytoDyn Summary page, I'm a lot from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *